

Cofc

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on August 23, 2006.

REQUEST FOR CERTIFICATE OF
CORRECTION UNDER 37 C.F.R. 1.322
Docket No. BB-112T
Patent No. 7,067,474 B1

David Saliwanchik
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Walter Birchmeier, Jens-Peter Von Kries
Issued : June 27, 2006
Patent No. : 7,067,474 B1
Application No. : 09/641,104
For : Agents for Treating Human Illnesses, Based on β -Catenin, and
the Production and Use Thereof

Mail Stop Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate
AUG 31 2006
of Correction

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 CFR 1.322 (OFFICE MISTAKE)

Sir:

A Certificate of Correction (in duplicate) for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where errors occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears.

AUG 31 2006

Patent Reads:Cover Page:

“(30) **Foreign Application Priority Data**
Feb. 21, 1998 (DE) 198 07 390”

Column 1, line 16:

“LEF-1-TCF-4”

Column 1, line 30:

“ α -catenin”

Column 1, line 33:

“ α -catenin”

Column 1, line 36:

“ α -catenin”

Column 1, line 37:

“ α -catenin”

Application Reads:Page 2 of Examiner's Amendment dated May 26, 2005:

--This application is a continuation of International Application No. PCT/DE99/00554, filed February 21, 1999, which claims priority of German Patent Application No. 198 07 390.9, filed February 21, 1998, the contents of which are incorporated herein by reference thereto.--

Filing Receipt dated October 4, 2000:**--Foreign Applications**

GERMANY 198 07 390.9
02/21/1998--

Page 1, line 8:

--LEF-1/TCF-4--

Page 1, line 17:

-- β -catenin--

Page 1, line 19:

-- β -catenin--

Page 1, line 21:

-- β -catenin--

Page 1, line 22:

-- β -catenin--

Patent Reads:Column 1, line 41:“ α -catenin”Column 1, line 45:

“beta-catenin-Tef”

Column 1, lines 54-55:

“mutation. % in”

Column 1, line 55:“ α -catenin”Column 1, line 56:“ α -catenin”Column 1, line 57:

“beta-catenin-Tef”

Column 3, line 51:“ β -catenin produced”Column 4, line 32:

“corresponds t)”

Column 5, line 14:

“LEF-TCF”

Column 5, line 52:

“averaged (or”

Application Reads:Page 1, line 25:-- β -catenin--Page 1, line 28:

--beta-catenin-Tcf--

Page 2, line 1:

--mutations in--

Page 2, lines 1-2:-- β -catenin--Page 2, line 2:-- β -catenin--Page 2, line 3:

--beta-catenin-Tcf--

Page 4, line 33:-- β -catenin were produced--Page 6, line 1:

--corresponds to--

Page 7, line 7:

--LEF-1/TCF--

Page 8, line 4:

--averaged for--

Patent Reads:Column 6, line 7:

“endogenic & catenin”

Column 6, line 42:

“405 mm”

Column 6, line 63:“Leu218-Leu71 μ l or”Column 7, line 4:

“Ser1259Asp 1400”

Column 8, line 1:

““Comparison of the”

Column 8, line 3:

“amino acids.””

Column 8, line 15:

“in all repeats”

Column 8, line 43:

“FIGS 8A and 8B:”

Column 8, lines 44-45:“Substances binding in the hydrophobic pocket of β -catenin. Representation of the”**Application Reads:**Page 8, lines 21-22:--endogenic β -catenin--Page 9, line 19:

--405 nm--

Page 10, line 3:

--Leu218-Leu781 or--

Page 10, lines 7-8:

--Ser1259-Asp 1400--

Page 12, line 13:

--B. Comparison of the--

Page 12, line 14:

--amino acids.--

Page 12, line 24:

--in all repeats--

Page 4 of the Amendment dated August 20, 2003, Line 7:

--FIG. 8:--

Page 4 of the Amendment dated August 20, 2003, Lines 9-11:--Substances binding in the hydrophobic pocket of β -catenin.
A. Representation of the--

Patent Reads:Column 9, line 2:

“1-catenin”

Column 9, line 7:

“(“drug, list”)

Column 10, lines 4-20:

“binding site in the pocket.

Tab. 1


Amino acid sequence of the human β -catenin (armadillo repeats 3 8).

TABLE 2

Interaction between β -catenin mutants and LEF-1, APC(20 and 15 amino acid repeats), conductin and E-cadherin

| β -catenin mutants | arm, units | LEF-1 | APC-20 | interaction with APC-15 | conductin | E-cadherin |
|---|------------|-------|--------|-------------------------|-----------|------------|
| The values give the share of the respective interaction with the wild type β -catenin in percent. Interactions marked by - correspond to 60 100% of the wild type interaction. The values were determined in yeast 2-hybrid assays. | | | | | | |

FIG. 1”


Column 30, line 13:**Application Reads:**Page 13, line 9:-- β -catenin--Page 4 of the Amendment dated August 20, 2003, Lines 32-33:

--(“drug list”)--

Pages 3-5 of the Amendment dated August 20, 2003, Replacement Sheets Tables 1-2:

--binding site in the pocket.

FIG. 1--

Examiner's Amendment dated May 26, 2005, Table 4, Page 4:

A true and correct copies of pages 1-2, 4, 6-10, and 12-13 of application as filed, Filing Receipt dated October 4, 2000, pages 3-5 and Replacement Sheets Tables 1-2 of the Amendment dated August 20, 2003, and Examiner's Amendment dated May 26, 2005, which support Applicants' assertion of the errors on the part of the Patent Office accompanies this Certificate of Correction.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRS/an

Attachments: Certificate of Correction in duplicate;
Copy of pages 1-2, 4, 6-10, and 12-13 of the application as filed;
Copy of Filing Receipt dated October 4, 2000;
Copy of pages 3-5 and Replacement Sheets Tables 1-2 of the Amendment dated August 20, 2003; and
Copy of Examiner's Amendment dated May 26, 2005.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,067,474 B1

Page 1 of 4

APPLICATION NO.: 09/641,104

DATED : June 27, 2006

INVENTORS : Walter Birchmeier, Jens-Peter Von Kries

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Cover Page.

“(30) **Foreign Application Priority Data**
Feb. 21, 1998 (DE) 198 07 390”

should read

--(30) **Foreign Application Priority Data**
Feb. 21, 1998 (DE) 198 07 390.9--.

Column 1.

Line 16, “LEF-1-TCF-4” should read --LEF-1-/TCF-4--.

Line 30, “ α -catenin” should read -- β -catenin--.

Line 33, “ α -catenin” should read -- β -catenin--.

Line 36, “ α -catenin” should read -- β -catenin--.

Line 37, “ α -catenin” should read -- β -catenin--.

Line 41, “ α -catenin” should read -- β -catenin--.

Line 45, “beta-catenin-Tef” should read --beta-catenin-Tcf--.

Lines 54-55, “mutation. % in” should read --mutations in--.

Line 55, “ α -catenin” should read -- β -catenin--.

Line 56, “ α -catenin” should read -- β -catenin--.

Line 57, “beta-catenin-Tef” should read --beta-catenin-Tcf--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

AUG 31 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,067,474 B1

Page 2 of 4

APPLICATION NO.: 09/641,104

DATED : June 27, 2006

INVENTORS : Walter Birchmeier, Jens-Peter Von Kries

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3,

Line 51, "β-catenin produced" should read --β-catenin were produced--.

Column 4,

Line 32, "corresponds t)" should read --corresponds to--.

Column 5,

Line 14, "LEF-TCF" should read --LEF-1/TCF--.

Line 52, "averaged (or)" should read --averaged for--.

Column 6,

Line 7, "endogenic & catenin" should read --endogenic β-catenin--.

Line 42, "405 mm" should read --405 nm--.

Line 63, "Leu218-Leu71 μl or" should read --Leu218-Leu781 or--.

Column 7,

Line 4, "Ser1259Asp 1400" should read --Ser1259-Asp 1400--.

Column 8,

Line 1, ""Comparison of the" should read --B. Comparison of the--.

Line 3, "amino acids."" should read --amino acids--.

Line 15, "in all repeats" should read --in all repeats--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

AUG 31 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,067,474 B1

Page 3 of 4

APPLICATION NO.: 09/641,104

DATED : June 27, 2006

INVENTORS : Walter Birchmeier, Jens-Peter Von Kries

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 8,

Line 43, "FIGS 8A and 8B:" should read --FIG. 8:--.

Lines 44-45, "Substances binding in the hydrophobic pocket of β -catenin. Representation of the" should read --Substances binding in the hydrophobic pocket of β -catenin.

A. Representation of the--.

Column 9,

Line 2, "1-catenin" should read -- β -catenin--.

Line 7, "(("drug, list"))" should read --("drug list")--.

Column 10,

Lines 4-20,

"binding site in the pocket.

Tab. 1

Amino acid sequence of the human β -catenin (armadillo repeats 3 8).

TABLE 2

Interaction between β -catenin mutants and LEF-1, APC(20 and 15 amino acid repeats).
conductin and E-cadherin

| β -catenin mutants | interaction with | | | |
|--------------------------|------------------|-------|--------|-----------------------------|
| | arm, units | LEF-1 | APC-20 | APC-15 conductin E-cadherin |

The values give the share of the respective interaction with the wild type β -catenin in percent. Interactions marked by - correspond to 60 100% of the wild type interaction. The values were determined in yeast 2-hybrid assays.

FIG. 1" should read --binding site in the pocket. FIG. 1--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

AUG 31 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,067,474 B1

Page 4 of 4

APPLICATION NO.: 09/641,104


DATED : June 27, 2006

INVENTORS : Walter Birchmeier, Jens-Peter Von Kries


It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 30,

Line 13,



should read



MAILING ADDRESS OF SENDER:
Saliwanchik, Lloyd & Saliwanchik
P.O. Box 142950
Gainesville, FL 32614-2950

AUG 31 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,067,474 B1

Page 1 of 4

APPLICATION NO.: 09/641,104

DATED : June 27, 2006

INVENTORS : Walter Birchmeier, Jens-Peter Von Kries

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Cover Page.

“(30) **Foreign Application Priority Data**
Feb. 21, 1998 (DE) 198 07 390”

should read

--(30) **Foreign Application Priority Data**
Feb. 21, 1998 (DE) 198 07 390.9--.

Column 1.

Line 16, “LEF-1-TCF-4” should read --LEF-1-/TCF-4--.

Line 30, “ α -catenin” should read -- β -catenin--.

Line 33, “ α -catenin” should read -- β -catenin--.

Line 36, “ α -catenin” should read -- β -catenin--.

Line 37, “ α -catenin” should read -- β -catenin--.

Line 41, “ α -catenin” should read -- β -catenin--.

Line 45, “beta-catenin-Tef” should read --beta-catenin-Tcf--.

Lines 54-55, “mutation. % in” should read --mutations in--.

Line 55, “ α -catenin” should read -- β -catenin--.

Line 56, “ α -catenin” should read -- β -catenin--.

Line 57, “beta-catenin-Tef” should read --beta-catenin-Tcf--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

AUG 31 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,067,474 B1

Page 2 of 4

APPLICATION NO.: 09/641,104

DATED : June 27, 2006

INVENTORS : Walter Birchmeier, Jens-Peter Von Kries

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3,

Line 51, "β-catenin produced" should read --β-catenin were produced--.

Column 4,

Line 32, "corresponds t)" should read --corresponds to--.

Column 5,

Line 14, "LEF-TCF" should read --LEF-1/TCF--.

Line 52, "averaged (or" should read --averaged for--.

Column 6,

Line 7, "endogenic & catenin" should read --endogenic β-catenin--.

Line 42, "405 mm" should read --405 nm--.

Line 63, "Leu218-Leu71 μl or" should read --Leu218-Leu781 or--.

Column 7,

Line 4, "Ser1259Asp 1400" should read --Ser1259-Asp 1400--.

Column 8,

Line 1, ""Comparison of the" should read --B. Comparison of the--.

Line 3, "amino acids."" should read --amino acids--.

Line 15, "in all repeals" should read --in all repeats--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

AUG 31 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,067,474 B1

Page 3 of 4

APPLICATION NO.: 09/641,104

DATED : June 27, 2006

INVENTORS : Walter Birchmeier, Jens-Peter Von Kries

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 8,

Line 43, "FIGS 8A and 8B:" should read --FIG. 8:--.

Lines 44-45, "Substances binding in the hydrophobic pocket of β -catenin. Representation of the" should read --Substances binding in the hydrophobic pocket of β -catenin.

A. Representation of the--.

Column 9,

Line 2, "1-catenin" should read -- β -catenin--.

Line 7, "(("drug, list"))" should read --("drug list")--.

Column 10,

Lines 4-20,

"binding site in the pocket.

Tab. 1

Amino acid sequence of the human β -catenin (armadillo repeats 3 8).

TABLE 2

Interaction between β -catenin mutants and LEF-1, APC(20 and 15 amino acid repeats).
conductin and E-cadherin

| β -catenin mutants | arm, units | interaction with | | | |
|--------------------------|---------------|------------------|--------|--------|----------------------|
| | | LEF-1 | APC-20 | APC-15 | conductin E-cadherin |

The values give the share of the respective interaction with the wild type β -catenin in percent. Interactions marked by - correspond to 60 100% of the wild type interaction. The values were determined in yeast 2-hybrid assays.

FIG. 1" should read --binding site in the pocket. FIG. 1--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

AUG 31 2006

CERTIFICATE OF CORRECTION


Page 4 of 4

DATED : June 27, 2006


INVENTORS : Walter Birchmeier, Jens-Peter Von Kries

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Line 13,




should read



AUG 31 2006

Canadian version based on WO 99/42481



AGENTS FOR TREATING HUMAN ILLNESSES BASED ON β -CATENIN, AND THE PRODUCTION AND USE THEREOF

Description

The invention relates to agents for treating human illnesses based on substances affecting the interaction between β -catenin and transcription factors and tumor suppressor gene products. Among them there are LEF-1-/TCF-4-transcription factors and peptides derived from β -catenin and similar molecules. Furthermore, it relates to a method for detecting such substances and the use of the agent, preferably for treating tumors such as colonic cancers and melanomas.

Accordingly, fields of application of the invention are pharmaceutical industry and medicine.

β -catenin is a cytoplasmic protein which fulfils various functions in the cell. In complex with the cell adhesion molecules of the cadherin family β -catenin establishes the connection with the cytoskeleton (Huelsenken J. et al., E-cadherin and APC compete for the interaction with β -catenin and the cytoskeleton. J-Cell-Biol. 127: 2061-9, 1994). In addition, β -catenin is a component of the Wnt signal transduction which plays a big part in embryonic development. The transcription factor LEF-1 was identified as interaction partner of β -catenin in this signal cascade (Behrens, J. et al., Functional interaction of β -catenin with the transcription factor LEF-1. Nature, 382: 638-42, 1996). The mechanism of signal transduction by β -catenin and LEF-1 has been clarified: It consists of the transport of β -catenin into the cell nucleus mediated by LEF-1. This complex regulates the gene expression in the cell nucleus by the LEF-1 induced DNA flexion modified in the complex and by the carboxy-terminal transactivation domain of β -catenin. In the mean time, there has been shown that also other members of the LEF-1/TCF family of transcription factors, e.g. TCF-4, are able to mediate this signal transduction (Korinek, V. et al., Constitutive transcriptional activation by a β -catenin-Tcf complex in APC-/colon carcinoma. Science, 275: 1784-87, 1997).

Stabilizing the cytoplasmic pool of free β -catenin not bound to cadherin is the prerequisite to this signal transduction depending on β -catenin. This pool is negatively regulated by glycogen synthetase kinase 3 β , by the tumor suppressor gene product APC and conductin/axin.

There was shown for cancers and melanomas that mutations in the N-terminal area of β -catenin or in the β -catenin binding domain of APC stop this regulation (Morin, P.J. et al., Activation of beta-catenin-Tcf signaling in colonic cancer by mutations in beta-catenin or APC. Science, 275: 1787-90, 1997). Accordingly, the β -catenin pool is stabilized. In melanomas this stabilization results in a LEF-1 mediated translocation of β -catenin into the cell nucleus whereas in colonic cancers this function is primarily fulfilled by TCF-4. The transcriptional activity of the complex in cancer cell lines is detected by activating a reporter gene. In addition, it has been shown that this activity is inhibited in APC-deficient colonic cancer cell lines after transfection of APC.

APC mutations were identified in the overwhelming majority of colonic cancers whereas not-APC-deficient tumors show mutations in the β -catenin gene. The result of these mutations of APC or β -catenin is an activation of signal transduction by the β -catenin-LEF/TCF complex. This underlines the key role played by β -catenin in the development of tumors. As APC mutations were identified as an early event in the development of colonic tumors the activation of the β -catenin-LEF/TCF complex is certainly a central step in the development of tumors.

Attempts have been made to utilize the key role played by β -catenin in the development of tumors for the development of therapeutic agents for treating tumors. Nearly at the same time, two patent applications were filed in the USA which, in the mean time, were published as WO papers. In WO 98/41631 (John Hopkins University – B. Vogelstein) the influence on interactions of β -catenin, TCF-4 and the tumor suppressor protein APC aimed at preventing the development of cancer is claimed. There was shown that products of mutated APC genes detected in colorectal tumors are no longer able to regulate the activation of the β -catenin/TCF-4 transcription. Furthermore, colorectal tumors with intact APC genes show activation mutations of β -catenin in the N-terminal area which affects the functioning of the most important phosphorylation sites. Based on this data, the conclusion is drawn that the regulation of β -catenin is critical for the tumor suppressor effect of APC and this regulation may be evaded by mutations in APC or in β -catenin. The main claim relates to the intron-free DNA molecule coding for TCF-4.

WO 98/42296 (Onyx Pharmaceuticals Inc. – Rubinfeld) relates to compositions and methods of diagnosing and treating illnesses caused by interactions between β -catenin and transcription

Furthermore, peptides where acid amino acids are arranged at a distance of 5 amino acids and flanked by hydrophobic and basic amino acids are preferred (Fig. 2).

These peptides may be used for treating tumors according to the invention with two principle ways being possible.

a) Use of peptides as such

A direct use of peptides for treating tumors is, in general, out of question owing to their instability towards proteases and owing to the lack of membrane permeability. Stabilizing is effected by coupling with a second peptide, for which the so-called antennapedia peptide RQIEIWFQNRMEWEE is excellently suited. This peptide is in a position to transport up to 100 amino acid long, coupled peptides through cell membranes into the cytoplasm and the cell nucleus. The coupled peptides may be used in treating tumors in a favourable way.

b) Use of peptides for drug design (peptide mimikry)

The peptides according to the invention serve also as a basis for designing substances which increase the stability and efficiency in the cell by a purposeful modification (peptidomimetics). This may be e.g. reached by adding reactive groups, substituting amino acids or design of non-hydrolyzable peptide-like bonds.

By substituting the carbon skeleton of the peptides by synthetic carbon skeletons with the same arrangement of functional groups the stability of the molecules may be also increased (non-peptidomimetics). This molecular mimikry of the biological activity of inhibitory peptides derived from the minimum binding domain of LEF-1/TCF for β -catenin (Figs. 3 and 4) allows the production of more potent agents for treating tumors.

In a second step to implement the invention the regions of β -catenin which are responsible for the specific bonds with LEF-1/TCF-4, APC domains (containing 20 and 15 amino acid repeats), conductin and E-cadherin were identified. It was detected that these regions overlap partly and concern the armadillo domains 3-8 of β -catenin (Figs 5 and 6). The central point of this surprising finding is that mutations of β -catenin were produced which prevent specific

LEF-1 which corresponds to the amino acids 7-29 in TCF-4 (Fig. 2). The interaction of N-terminal LEF-1 fragments with β -catenin was detected by means of activating a lacZ reporter gene (s. example).

In an ELISA with synthetic peptides there was shown that the respective peptides (11-34, 14-27) inhibit specifically the formation of the β -catenin/LEF-1 complex. Analogous principles apply to the TCF4 peptides 7-29 and 10-23 as regards the formation of the β -catenin/TCF-4 complex (Fig. 2).

The amino acids essential to the inhibition were identified by the synthesis of mutant peptides (Fig. 2). A symmetric arrangement of acid amino acids (aspartic acid and glutamic acid) at a distance of 5 amino acids flanked by hydrophobic amino acids (leucine, isoleucine) and a basic amino acid (lys) is essential to the functioning of peptides. The substitution of phenyl alanine or lysine by alanine stops also the inhibition by the peptide. The importance of acid and aromatic amino acid residues was confirmed by a nucleus translocation test (Fig. 4) of endogenous β -catenin and by a transactivation test in mammalian cells in the context of the whole LEF-1 molecule.

2. Characterization of the interaction domain of β -catenin for LEF-1, APC, conductin and E-cadherin

The armadillo area of β -catenin was crystallized by Huber et al. in 1997 and characterized by the X-ray crystallographic analysis. It was possible to identify a basic groove which might be responsible for the interaction with the acid amino acids of LEF-1 (see above). That is why basic (Lys, Arg, His) and some aromatic (Trp) amino acids were mutated in the armadillo repeat units 3-9 of β -catenin (Fig. 5). Attention was paid to the fact that notably free amino acid residues of helices 3 forming the basis of the groove and some amino acid residues of the periphery (helix 1) were mutated. The mutant β -catenins were tested if they still interact with the interaction partners LEF/TCF, APC, conductin and E-cadherin (Tab. 2). With the aid of this method it was possible to identify critical amino acid residues of β -catenin which are of importance to specific interactions (Figs. 5 and 6). Thus it was possible to identify specific regions of β -catenin for the individual interaction partners (Fig. 6). These regions are

important for identifying molecules affecting specifically the interaction of β -catenin with LEF-1, APC, conductin or E-cadherin.

The finding that the binding domains of β -catenin overlap partially for LEF-1/TCF, APC, conductin and E-cadherin is essential to the selection of new therapeutic agents. The selection is e.g. carried out in the following way: Substance libraries are tested whether they affect specifically the interaction between β -catenin and LEF-1/TCF, β -catenin and APC (20 or 15 amino acid repeats), β -catenin and conductin or β -catenin and E-cadherin. Thereupon, peptides or similar surface structures of the armadillo repeats 3-8 of β -catenin can be generated which were identified by mutation of β -catenin and these can subsequently be tested for their effect on binding of various interaction partners.

The interaction with LEF-1/TCF-4 is of an oncogenic nature, i.e. promotes potentially the development of cancer, the interactions with APC, conductin and E-cadherin are potentially anti-oncogenic, i.e. they inhibit the development of cancer. Each new substance interfering in the Wnt signal path has to be therefore carefully tested for its specific effect. The characterization of the binding domain of β -catenin presented here is the basis for that. Substances reducing specifically the β -catenin/LEF-1/TCF-4 interaction are therefore potential anti-cancer therapeutic agents. Substances inhibiting the interaction with APC, conductin or E-cadherin promote potentially the Wnt signal path and may be used for an intensified development of tissue, e.g. for promoting the growth of hair.

Hereinafter, the invention shall be explained in greater detail by way of examples:

1. Identification of the minimum binding domain of LEF-1 for β -catenin:

The interaction between the partial domains of LEF-1 and β -catenin was analyzed in the yeast-2 hybrid system by determining the activity of β -galactosidase according to information of the producer (Clontech) (Fig. 1). For this purpose the DNA coding for the N-terminal partial domains of LEF-1 was inserted into the cloning site of the Lex-A DNA binding domain which contains vector BTM116 and checked by sequencing. The DNA fragments of LEF-1 were prepared by a polymerase chain reaction (PCR)

and incubation with restriction endonucleases. The DNA coding for β -catenin was cloned into the vector pGAD424 (Clontech) for the activation domain of GAL-4 (Behrens et al. 1996). The β -galactosidase activities of independent experiments were averaged for comparing the interaction of the hybrids.

The specificity of the interaction of the LEF-1 hybrids with β -catenin was checked by means of the β -galactosidase activity of yeasts producing the LEF hybrids and the GAL-4 activation domain without β -catenin (Fig. 1). The expression of the LEF-1 hybrids was checked in an immunoblot with yeast cell lysates by antibodies (Clontech) as against the Lex-A domain of the hybrids. Equal yeast quantities were used for preparing the lysates after determining the optical density of the cultures.

2. Characterization of the β -catenin binding domain of LEF-1 in the test for translation

By an in vitro mutagenesis of the cDNA of LEF-1 point mutations were generated in the binding domain of LEF-1 for β -catenin. The mutagenesis was achieved by means of the "transformer site-directed mutagenesis kit" of the company Clontech according to information of the producer. The following amino acids were substituted by alanine: Glu 14, Asp 19, Glu 20, Phe 24, Lys 25, Asp 26 and Glu 27. The mutants were checked by sequencing and subcloned into the vector pCG-LEF-1 (Behrens et al. 1996). After the transfection of MDCK cells with LEF-1 or its mutants the translocation of endogenic β -catenin into the cell nucleus was analyzed according to immunocytological methods. To this end, 2.5×10^5 MDCK cells were transfected. The immunodetection of LEF-1 was carried out with an anti LEF-1 serum of rabbits and Cy2 conjugated anti-rabbit antibodies, the detection of β -catenin was achieved by means of monoclonal antibodies and Cy-3 conjugated anti-mouse antibodies (Fig. 4A).

3. Characterization and quantification of inhibitory peptides in an ELISA:

Both proteins were produced in bacteria recombinantly with N-terminal histidine sequences, purified by means of nickel chromatography for quantifying the inhibition of the LEF-1/ β -catenin interaction by synthetic peptides and (Behrens et al. 1996). The peptides were produced by the company Biosyntan with the aid of a PSSM-8 automaton (Shimadzu, Japan) applying the Fmoc/But strategy (E. Atherton and R.C. Sheppard. 1989 IRL Press, Oxford: "Solid phase peptide synthesis – a practical approach"). Approx. 50 ng of LEF-1 were absorbed in the wells of ELISA plates for 90 minutes at room temperature. Subsequently, the wells were covered with 5 % dry milk powder in PBS for 16 hours at 4°C. All further steps were carried out at room temperature in PBS with 50 mM Tris HCl (pH 7.5). After washing the wells with PBS the peptide dilutions were added. The incubation with 50 – 100 ng of β -catenin was carried out for 10 minutes in the presence of 200 mg/ml BSA. The complex formation of LEF-1 and β -catenin was detected by the antibody PA2 against the carboxy terminal area of β -catenin (Huelsenken et al. 1994). PA2 was added in a standard dilution of 1:5000 in 3 % of dry milk powder in PBS for 10 minutes. After washing the wells with PBS a quantification was carried out by detection antibodies conjugated by peroxidase (1 : 2500 in 3 % of dry milk powder in PBS, Dianova) and the conversion of o-phenylenediamine was determined by photometric measurement at 405 nm. The peptides were used in concentrations of 100 μ M to 0.3 μ M. To check the specificity of the inhibition of the LEF1/ β -catenin interaction β -catenin was absorbed in the wells and detected by means of the same antibodies in the presence and absence of the peptides (Figs. 2 and 3).

For a mutation analysis of the peptides the indicated amino acids were substituted by alanine during the synthesis. The inhibition of the complex formation of β -catenin and LEF-1 was quantified as has been already described (Fig. 2).

4. Preparation and testing of mutants of β -catenin modulating the interaction with LEF-1, APC, conductin or E-cadherin

The mutagenesis of β -catenin in the armadillo repeats 3-8 was carried out by means of the "mutagenesis kit" of the company Clontech according to the producer's record and the mutants were checked by sequencing (Fig. 5). In all mutants the original amino acid was

substituted by alanine. For analyzing the interactions the cDNA of human β -catenin (armadillo repeat 3 up to the C-terminal end of the protein) coding for the amino acids Leu218-Leu781 or its mutants was cloned into the fusion vector for the activation domain of Gal-4 (pGAD424, Clontech). The cDNA for the binding domains of the interaction partners was cloned into the LexA fusion vector BTM116. To this end, the cDNA of LEF-1 for the amino acids 1-99, conductin for the amino acids Ala342-ARG465; of human APC for the amino acids His1012-Glu1215 (APC 15 amino acid repeats) and for the amino acids Ser1259-Asp 1400 (APC 20 amino acid repeats) and E-cadherin for the amino acids Gln773-Asp884 (cytoplasmatic domain) were amplified with the respective primers PCR. The interaction of the Lex-A hybrids with β -catenin and its mutants was quantified by means of the β -galactosidase reporter activity in the yeast 2-hybrid system (report:"Matchmaker", Clontech) (Tab. 2 and Fig. 6).

Fig. 4:

A substitution of acid amino acid residues and of ~~phenyl alanine~~ ^{phenylalanine} in the minimum binding domain of LEF-1 blocks the translocation of β -catenin into the cell nucleus.

- A. MDCK cells were transfected with wild type and mutants of LEF-1 and the translocation of endogenous β -catenin into the cell nucleus was checked by an immunofluorescence detection. The substitution of the acid amino acid residues of Asp19, Glu20, Asp26 and Glu27 by alanine blocks the translocation of β -catenin into the cell nucleus; the substitution of the aromatic amino acid Phe24 has the same effect. The substitution of Glu14 and Lys25 does not prevent a translocation. Arrows mark the cells transfected by LEF-1 in the immunodetection for endogenic β -catenin.
- B. Comparison of the minimum binding domains of LEF-1 and TCF-4 with the respective positions of the amino acids.

Fig. 5:

Mutations of alanine in the armadillo domain of β -catenin resulting in a reduction of more than 70 % of the interaction with LEF-1, APC, conductin and E-cadherin.

The localization of the mutations related to the structural context (Helix 1-3, in frames) is represented. The figures above the amino acids in the sequence mark the analyzed mutants. The mutants with a reduction of the interaction with LEF-1 (red), APC (blue), conductin (green) and E-cadherin (yellow) of more than 70 % are marked by various colours. Amino acids marked grey represent in all repeats preserved identical or chemically similar amino acids.

Fig. 6:

Mutations in the armadillo domain of β -catenin preventing specifically only binding of LEF-1, APC, conductin and e-cadherin.

Representation of the armadillo domain repeats 3-8 with mutations showing a reduction of the respective interaction to less than 30 % (red) or to 30-60 % (yellow). Mutants which are specific for the respective interaction: Arg469 and His470 for binding LEF-1, Trp383 for

APC (20 amino acid repeats), Arg386 for APC (15 amino acid repeats), Phe253, Arg274 and Trp338 for conductin are marked by arrows. The interactions were determined in a yeast 2-hybrid system by means of the β -galactosidase reporter activity.

Tab. 1:

Amino acid sequence of the armadillo repeats 3-8 of human β -catenin

Tab. 2:

Compilation of all β -catenin mutants with a binding activity of less than 60 % towards the binding domains of LEF-1, APC, conductin and E-cadherin indicated



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

| APPLICATION NUMBER | FILING DATE | GRP ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO | DRAWINGS | TOT CLAIMS | IND CLAIMS |
|--------------------|-------------|--------------|---------------|-----------------|----------|------------|------------|
| 09/641,104 | 08/17/2000 | | 0 | 0107-028P | 27 | 1 | 1 |

23622
GABRIEL P KATONA, LLP
708 THIRD AVE, 14TH FLOOR
NEW YORK, NY 10017

FILING RECEIPT



OC000000005449664

RECEIVED

OCT 10 2000

Date Mailed: 10/04/2000

Gabriel P. Katona

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Walter Birchmeier, Residence Not Provided;
Jens-Peter Von Kries, Residence Not Provided;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CON OF PCT/DE99/00554 02/21/1999

Foreign Applications

GERMANY 198 07 390.9 02/21/1998

If Required, Foreign Filing License Granted 10/03/2000

Title

Unknown

Preliminary Class

Data entry by : ASFAW, MULUGETA

Team : OIPE

Date: 10/04/2000



AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph beginning at page 11, line 18, with the following rewritten paragraph:

Synthetic peptides from the N-terminal area of hTCF-4 with substitutions of the amino acid residues indicated were tested for their ability to inhibit the interaction between LEF-1 and β -catenin. The substitution of the acid amino acid residues of Asp10, Asp15 and Asp22 of TCF-4 by ~~aniline~~ alanine results in stopping the inhibition by the respective peptides. The substitution of Phe20 and Lys21 has the same effect. By a deletion an acid, minimum binding domain of TCF-4 for β -catenin of a length of 14 amino acids (Asp 10 up to Glu23) was identified.

Please replace the paragraph beginning at page 12, line 2, with the following rewritten paragraph:

A substitution of acid amino acid residues and of ~~phenyl-alanine~~ phenylalanine in the minimum binding domain of LEF-1 blocks the translocation of β -catenin into the cell nucleus.

Please add the following new paragraph describing figures 7-9 after the paragraph ending on line 3 of page 13 (before the line starting with "Tab 1:"):

Fig. 7:

Characterization of a hydrophobic pocket adjacent to the essential binding sites of β -catenin for LEF-1/TCF

- A. View of the hydrophobic pocket at the molecule surface of β -catenin (RasMol). The pocket is flanked by amino acids marked in orange or yellow colours. The amino acid

residues of the essential binding site for LEF/TCF are marked in blue colour. The respective amino acids have been marked.

B. Side view of hydrophobic pocket.

Fig. 8:

Substances binding in the hydrophobic pocket of β -catenin

A. Representation of the surface of the hydrophobic pocket region (Grasp). The amino acid residues of the essential binding site for LEF/TCF are marked in blue colour (for mutations blocking the interaction between β -catenin and LEF/TCF: Lys435, Arg 469 and His 470). In the β -catenin molecule one of the low-molecular substances binding in the pocket is represented.

Fig. 9:

Cefamandole as a representative of molecule class I inhibits the complex formation of LEF-1 and β -catenin in an ELISA.

Rising concentrations of cefamandole (15-250 μ M) result in a reduction of the complex formation of LEF-1 and β -catenin protein prepared recombinantly and purified in an ELISA (IC₅₀=25 μ M).

Please add the following new paragraph after the paragraph ending on line 12 of page 13:

Tab. 3:

Substances potentially binding in the hydrophobic pocket ("drug list")

Tab. 4:

“Positive list” of substances inhibiting the complex formation or
stopping the inhibition by competition around the binding site in
the pocket.

Please replace Tables 1 –4 with the replacement Tables 1-4 which has the translated German to
English text. These are attached below.

REPLACEMENT SHEET

Tab. 1

Amino Acid Sequence of the Human β -catenin (Armidillo Repeats 3-8)

| | | |
|-------|-----------|--|
| arm 3 | (224-264) | HREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLL |
| arm 4 | (265-306) | HQEGA MAVRLAGGLQKMVALLNKTNVKFLAITTDCQLLAY |
| arm 5 | (307-349) | GNQESKLIILASGGPQALVNIIMRTYTYEKLWTTSRVLKVLVS |
| arm 6 | (350-390) | CSSNKP AIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSD |
| arm 7 | (391-429) | AATKQEGMEGLLGLTVQLLGSDDIINVVTCAAGILSNLTC |
| arm 8 | (430-473) | NNYKNKMMVVCQVGGIEALVRTVL RAGDREDITEPAICALRHLS |
| arm 9 | (474-519) | RHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLAL |

REPLACEMENT SHEET


Tab. 2

Interaction between β -Catenin Mutants and LEF-1, APC (20 and 15 Amino Acid Repeats), Conductin and E-Cadherin

| β -Catenin Mutants | arm. units | Interaction With | | | | |
|--------------------------|------------|------------------|--------|--------|-----------|------------|
| | | LEF-1 | APC-20 | APC-15 | Conductin | E-Cadherin |
| Phe 253 | 3 | - | 40 | - | 17 | - |
| His 260 | 3 | 50 | 40 | 100 | 10 | 100 |
| Arg 274 | 4 | - | 40 | - | 29 | 50 |
| Lys 292 | 4 | - | 28 | - | 5 | - |
| Trp 338 | 5 | - | 55 | - | 20 | - |
| Arg 342 | 5 | - | 29 | - | 20 | 41 |
| Lys 345 | 5 | 38 | 0 | - | 22 | 27 |
| Lys 354 | 6 | 38 | - | 54 | 43 | 40 |
| Trp 383 | 6 | - | 0 | 59 | - | - |
| Arg 386 | 6 | 35 | | 12 | 45 | - |
| Lys 394 | 7 | - | - | - | 42 | - |
| Lys 435 | 8 | - | - | 30 | 42 | - |
| Arg 457 | 8 | - | - | - | 36 | - |
| Arg 469 | 8 | 17 | - | - | - | 50 |
| His 470 | 8 | 2 | 47 | 60 | - | - |

The values give the share of the respective interaction with the wild type β -catenin in percent. Interactions marked by - correspond to 60-100% of the wild type interaction. The values were determined in yeast 2-hybrid assays.

Art Unit: 1653



An ~~Examiner's Amendment~~ to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.121. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with David Saliwanchik on May 19, 2005.

Examiner's Amendments to the specification:

-Please replace the paragraph (A₁), which is inserted by preliminary amendment filed August 17, 2000, at page 1 after the title with the following paragraph:

This application is a continuation of International Application No. PCT/DE99/00554, filed February 21, 1999, which claims priority of German Patent Application No. 198 07 390.9, filed February 21, 1998, the contents of which are incorporated herein by reference thereto.

-Please replace the third paragraph at page 11 with the following paragraph:

Fig. 2:

Characterization of the minimum binding domain of TCF-4 (residues 1-18 of SEQ ID NO:3) by inhibition of binding of β -catenin to LEF-1 in an ELISA.

-Please replace the phrase "Comparison of the minimum binding domains of LEF-I and TCF-4 with the respective positions of the amino acids." at page 12, paragraph 3 with the phrase "Comparison of the minimum binding domains of LEF-I (SEQ ID NO:2) and TCF-4 (SEQ ID NO:4) with the respective positions of the amino acids."

-Please replace the term "Fig. 5." at page 12, paragraph 4 with the term "Figs. 5a-5e."

-Please replace the paragraph describing Fig. 8 at page 4 of the amendment to Specification filed August 20, 2003 with the following paragraph:

Figs. 8A and 8B:

Art Unit: 1653

Substances binding in the hydrophobic pocket of β -catenin.

Representation of the surface of the hydrophobic pocket region (Grasp). The amino acid residues of the essential binding site for LEF/TCF are marked in blue color (for mutations blocking the interaction between β -catenin and LEF/TCF: Lys 435, Arg 469 and His 470). In the β -catenin molecule one of the low-molecular substances binding in the pocket is represented.

-Please replace the second paragraph describing Tab. 1 at page 13 with the following paragraph:

Tab. 1:

Amino acid sequence of the armadillo repeats 3-8 of human β -catenin: arm 3 (SEQ ID NO:6), arm 4 (SEQ ID NO:7), arm 5 (SEQ ID NO:8), arm 6 (SEQ ID NO:9), arm 7 (SEQ ID NO:10), arm 8 (SEQ ID NO:11) and arm 9 (SEQ ID NO:12).

- Please replace the Tab. 4 filed August 20, 2003 with the replacement sheet of Tab. 4 (see attached 4 pages):

Examiner's Amendments to the Claims:

Claims 45, 47 and 50 have been amended as follows:

45. (Currently amended) A peptide or polypeptide obtained from the armadillo domain of human β -catenin polypeptide which inhibits the interaction of human β -catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said peptide or polypeptide is selected from the group consisting of peptides or polypeptides consisting of the sequences shown in SEQ ID NO: 6 having a mutation in Phe in position 30, ~~or~~ a mutation in His in ~~position 37~~ position 37 or both; SEQ ID NO: 7 having a mutation in Arg in position 9, ~~or~~ a mutation in Lys in position 27 or both; SEQ ID NO: 8 having a mutation in Trp in position 32, ~~or~~ a mutation in Arg in position 36, ~~or~~ a mutation in Lys in position 39 or any combination of mutations thereof; SEQ ID NO: 9 having a mutation in Lys in position 5, ~~or~~ ~~a~~ ~~mutation in TRP~~ Trp in position 34, ~~or~~ a mutation in Arg in position 37 or any combination of mutations thereof; SEQ ID NO: 10 having a mutation in Lys in position 4; and SEQ ID NO: 11 having a mutation in Lys in position 6, ~~or~~ a mutation in Arg in position 28, ~~or~~ a mutation in Arg in position 40, ~~or~~ a mutation in His in position 41 or any combination of mutations thereof, wherein said mutation replaces the indicated amino acid with an aliphatic amino acid.

47. (Currently amended) The peptide or polypeptide according to claim ~~[[44]]~~ 45, wherein said mutation replaces the indicated amino acid with alanine, valine, leucine or isoleucine.

50. (Currently amended) The peptide of claim 47, wherein ~~the effect is to inhibit the~~

Art Unit: 1653

~~interaction of β -catenin and~~ said transcription factor or tumor suppressor protein is selected from the group consisting of lymphoid enhancer-binding factor-1 (LEF-1), T cell transcription factor-1 (TCF-1), 15 amino acid repeats of adenomatous polyposis coli 15 (APC-15), conductin, E-cadherin and 20 amino acid repeats of APC (APC-20).

The following is an **Examiner's Statement of Reasons for Allowance**: The following reference appears to be the closest art to the claimed invention: Huber *et al.* (Cell 90, 871-882 (September 7, 1997)) disclose the three dimensional structure of the armadillo repeat region of murine β -catenin, designated β -59, and its two 40 and 10 kDa fragments consisting of residues 134-550 and 551-671. However, the reference does not teach or suggest a polypeptide consisting of the sequence of SEQ ID NO: 6-11 or 12 (arm 3-9 of human β -catenin), or specific mutants thereof. Therefore, the claims are allowable over the art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 09/641,104

Page 6

Art Unit: 1653


Chih-Min Kam, Ph. D.

CMK

Patent Examiner

CMK

April 7, 2005





A handwritten signature in black ink, appearing to read "Jon Weber", with a long horizontal flourish extending to the right.

JON WEBER
SUPERVISORY PATENT EXAMINER


Tab. 4

Positive List





Molecule Class

IA (Inhibitors of the Cefamandole-type)**Cefamandole****Cefamandole-Nafate****Cefsulodin****Cefadroxil**

Molecule Class

IB**AC-(6-O-STEAROYL)-MURAMYL-ALA-D-ISOGLUTAMINE**


Positive List

Molecule Class **IC****3,6-DIHYDROXYBENZONORBORNANE****Molecule with Modulating Activity for Molecule Class 1****1-(4-FLUOROPHENYL)-3-PHENYLPYRROLIDINE-2,5-DIONE****(-)-COTININE****4-(2-HYDROXYOCTAHYDRO-1,3,4-METHENO-2H-CYCLOBUTA(CD)PENTALEN-2-YL)PHENOL**

REPLACEMENT SHEET


Positive List

Chiral




Ceftriaxone

Chiral



L-TRANS-EPOXYSUCCINYL-LEU-3-METHYLBUTYLAMIDE


Chiral




ANTHO-RNAMIDE

Positive List

REPLACEMENT SHEET



N-ACETYL-MURAMYL-ALA-ISOGLN-OH



1,3,5(10),6,8(14)-ESTRAPENTAEN-3-OL-17-ONE ACETATE